FORTE Raises Question of Excessive Treatment in Myeloma
Following is a transcript of their remarks: Vinay Prasad, MD: I'm back with Dr. Aaron Goodman and Dr. Al-Ola Abdallah and we're talking about ASH and multiple myeloma. We have an exciting study to discuss, the FORTE study. This is a three-arm study that looks at carfilzomib-containing regimens, which, to my knowledge, is not the official standard of care in multiple myeloma in the frontline setting, although some believe it plays a role, and they ask a very provocative question about the role of transplant and maintenance. Dr. Goodman, I wonder if you might summarize the FORTE study. What is ...
Source: medpagetoday.com